Background: Persistent gadolinium enhancement on MRI of the meninges in some children with low-grade astrocytomas (LGA) is a widely recognized phenomenon. The relationship of this finding with the clinical course is unclear. Methods: From a consecutive cohort of 282 children with pathologically confirmed LGA we identified all patients with asymptomatic gadolinium enhancement of the meninges found on surveillance MRI. A nested case-control study was performed, comparing patients with meningeal enhancement to controls without enhancement. Results: Twenty-one children were identified with meningeal enhancement. The median follow-up was 5.2 years with enhancement noted for a median of 2.2 years. The 5-year overall survival for this cohort was 91.2% (Greenwood SE 8.0%), and the 5-year progression-free survival was 20.9% (SE 11.9%). Five patients are now free of disease, while 15 continue to have stable disease. The overall and progression-free survival was not significantly different compared to controls. Conclusions: Gadolinium enhancement of the meninges on MRI may occur in a significant number of children with LGA, particularly juvenile pilocytic astrocytoma, but does not appear to affect progression-free or overall survival. Change in management based on this finding alone is unwarranted.

Keywords:
Astrocytoma, Pediatric, MRI enhancement, Meninges
1.
Duffner PK, Cohen ME, Myers MM, Heise HW: Survival of children with brain tumors: SEER Program, 1973–1980. Neurology 1986;36:597–601.
2.
Burger PC, Scheithauer BW: Tumors of the Nervous System. Bethesda, Armed Forces Institute of Pathology, 1994, ser 3, fasc 10.
3.
Gajjar A, Sanford RA, Heideman R, Jenkins JJ, Walter A, Li Y, Langston JW, Muhlbauer M, Boyett JM, Kun LE: Low-grade astrocytoma: A decade of experience at St. Jude Children’s Research Hospital. J Clin Oncol 1997;15:2792–2799.
4.
Fisher PG: Rethinking brain tumors in babies and more. Ann Neurol 1998;44:300–302.
5.
Kramer ED, Vezina LG, Packer RJ, Fitz CR, Zimmerman RA, Cohen MD: Staging and surveillance of children with central nervous system neoplasms: Recommendations of the neurology and tumor imaging committees of the Children’s Cancer Group. Pediatr Neurosurg 1994;20:254–263.
6.
Zeltzer PM, Friedman HS, Norris DG, Ragab AH: Criteria and definitions for response and relapse in children with brain tumors. Cancer 1985;56:1824–1826.
7.
Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, et al.: Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 1993;11:850–856.
8.
Wallner KE, Gonzales MF, Edwards MSB, Wara WM, Sheline GE: Treatment results of juvenile pilocytic astrocytoma. J Neurosurg 1988;69:171–176.
9.
Pech IV, Shuer LM, Peterson K: Indolent course of disseminated juvenile pilocytic astrocytoma. Neurology 1997;48:A35–36.
10.
Fisher PG, Tihan T, Goldthwaite PT, Wharam MD, Carson BS, Weingart JD, Williams JA, Foer DR, Burger PC: All childhood low-grade astrocytomas are not the same: Three decades experience at the Johns Hopkins Hospital. Proc Am Soc Clin Oncol 1998;17:534a.
11.
Lee E: Statistical Methods for Survival Data Analysis, ed 2. New York, Wiley & Sons, 1992.
12.
Pollack IF, Hurtt M, Pang D, Albright AL: Dissemination of low grade intracranial astrocytomas in children. Cancer 1994;73:2869–2878.
13.
Gajjar A, Bhargava R, Jenkins JJ, Heideman R, Sanford RA, Langston JW, Walter AW, Kutlesch JF, Muhlbauer M, Kun LE: Low-grade astrocytoma with neuraxis dissemination at diagnosis. J Neurosurg 1995;83:67–71.
14.
Mamelak AN, Prados MD, Obana WG, Cogen PH, Edwards MSB: Treatment options and prognosis for multicentric juvenile pilocytic astrocytoma. J Neurosurg 1994;81:24–30.
15.
McLaughlin JE: Juvenile astrocytomas with subarachnoid spread. J Pathol 1976;118:101–107.
16.
Mishima K, Nakamura M, Nakamura H, Nakamura O, Funata N, Shitara N: Leptomeningeal dissemination of cerebellar pilocytic astrocytoma. J Neurosurg 1992;77:788–791.
17.
Versari P, Talamonti G, D’Aliberti G, Fontana R, Colombo N, Casadei G: Leptomeningeal dissemination of juvenile pilocytic astrocytoma: Case report. Surg Neurol 1994;41:318–321.
18.
River Y, Schwartz A, Gomori JM, Soffer D, Siegal T: Clinical significance of diffuse dural enhancement detected by magnetic resonance imaging. J Neurosurg 1996;85:777–783.
19.
Hochman M, Naidich T, Kobetz S, Fernandez-Maitin A: Spontaneous intracranial hypotension with pachymeningeal enhancement on MRI. Neurology 1992;42:1628–1630.
20.
Fishman R, Dillion W: Dural enhancement and cerebral displacement secondary to intracranial hypotension. Neurology 1993;43:609–611.
21.
Good D, Ghobrial M: Pathologic changes associated with intracranial hypotension and meningeal enhancement on MRI. Neurology 1993;43:2698–2700.
22.
Pannullo S, Reich J, Krol G, Deck M, Posner J: MRI changes in intracranial hypotension. Neurology 1993;43:919–926.
23.
Blank S, Shakir R, Bindoff L, Bradey N: Spontaneous intracranial hypotension: Clinical and magnetic resonance imaging characteristics. Clin Neurol Neurosurg 1997;99:199–204.
24.
Krause I, Kornreich L, Waldman D, Garty B: MRI meningeal enhancement with intracranial hypotension caused by lumbar puncture. Pediatr Neurol 1997;16:163–165.
25.
Mokri B, Piepgras D, Miller G: Syndrome of orthostatic headaches and diffuse pachymeningeal gadolinium enhancement. Mayo Clin Proc 1997;72:400–413.
26.
Hannerz J, Ericson K, Bro Skejo H: MR imaging with gadolinium in patients with and without post-lumbar puncture headache. Acta Radiol 1999;40:135–141.
27.
Herman M, Pozzi-Mucelli R, Skrap M: CT and MRI findings after stereotactic resection of brain lesions. Eur J Radiol 1996;23:228–234.
28.
Kioumehr F, Dadsetan M, Feldman N, Mathison G, Moosavi H, Rooholamini S, Verma R: Postcontrast MRI of cranial meninges: Leptomeningitis versus pachymeningitis. J Comput Assist Tomogr 1995;19:713–720.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.